pulcalopride

Prucalopride

From Wikipedia, the free encyclopedia

Prucalopride, brand name Resolor / DuphaPro among others, is a drug acting as a selective, high affinity 5-HT4 receptor agonist[1] which targets the impaired motility associated with chronic constipation, thus normalizing bowel movements.

Movetis

From Wikipedia, the free encyclopedia

Movetis was a pharmaceutical company headquartered in Belgium. It was founded in 2006 as a spin-off from parent company Johnson & Johnson. The company specialized in pharmaceuticals for treating gastro-intestinal disorders. The primary drug produced by Movetis was Prucalopride (known by the brand name "Resolor") , indicated for cases of chronic constipation.

  1. Shire forges $565M buyout deal for Movetis
  2. Shire to buy Belgian drugmaker Movetis for $560mln

Linaclotide

Allergan > 2nd Quarter 2018

Gastrointestinal, Women’s Health & Diversified Brands

LINZESS® net revenues in the second quarter of 2018 were

$191.8 million,

an increase of 14.3 percent versus the prior year quarter.


From Wikipedia, the free encyclopedia

Linaclotide (marketed under the trade name Linzess in the US and Mexico, and as Constella elsewhere)[2] is a drug used to treat irritable bowel syndrome with constipation and chronic constipation with no known cause.

It is an oligo-peptide agonist of guanylate cyclase 2C and remains in the GI tract after it is taken orally. It was approved in the US and Europe in 2012.

Linaclotide, like the endogenous guanylin and uroguanylin it mimics, is an agonist that activates the cell surface receptor of guanylate cyclase 2C (GC-C). The medication binds to the surface of the intestinal epithelial cells. Linaclotide is minimally absorbed and it is undetectable in the systemic circulation at therapeutic doses. Activation of GC-C increases cyclic guanosine monophosphate (cGMP). Elevated cGMP stimulates secretion of chloride and bicarbonate and water into the intestinal lumen, mainly by way of cystic fibrosis transmembrane conductance regulator (CFTR) ion channel activation. This results in increased intestinal fluid and accelerated transit. By elevating cGMP, linaclotide is also considered to reduce activation of colonic sensory neurons, reducing pain; and activates colonic motor neurons, which increases smooth muscle contraction and thus promotes bowel movements.